

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number
WO 02/060864 A1

(51) International Patent Classification⁷: C07C 403/02,
403/14, 35/21, B01D 11/02, A23L 1/28, A61P 17/02

(21) International Application Number: PCT/US02/02423

(22) International Filing Date: 30 January 2002 (30.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/264,722 30 January 2001 (30.01.2001) US

(71) Applicant: SABINSA CORPORATION [US/US]; 121
Ethel Road, Unit #6, Piscataway, NJ 08854 (US).

(72) Inventor: MAJEED, Muhammed; 121 Ethel Road West,
Unit #6, Piscataway, NJ 08854 (US).

(74) Agents: MURRAY, Robert, M. et al.; Arent Fox Kintner
Plotkin & Kahn, PLLC, 1050 Connecticut Avenue, NW,
Suite 400, Washington, DC 20036 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PROCESS OF OBTAINING COMPOSITIONS OF STABLE LUTEIN AND LUTEIN DERIVATIVES

(57) Abstract: The present invention concerns methods of obtaining stable lutein and its derivatives. Additionally, the invention concerns various compositions comprising lutein, lutein esters, tetrahydrocurcuminoids, and carnosic acid.

WO 02/060864 A1

PROCESS OF OBTAINING COMPOSITIONS OF STABLE LUTEIN AND LUTEIN DERIVATIVES

BACKGROUND OF THE INVENTION

[0001] This application claims the benefit of U.S. Provisional Application No. 60/264,722, filed January 30, 2001.

[0002] Lutein is a carotenoid found in fruits and vegetables which has begun to acquire importance as a nutraceutical because of its antioxidant and immunomodulating/immunostimulating actions. These actions are manifested in its ability to reduce oxidative stress and/or depression of the immune system, in conditions such as age-related macular degeneration, cataracts, atherosclerosis, and some forms of cancer. Also, because of its yellow to red coloration and natural occurrence in human foods, lutein also is used as a food colorant.

[0003] Lutein suitable for nutraceutical and cosmetic uses can be found in the chromoplasts of flowers, fruits and roots (such as, but not limited to, carrots and yellow potatoes). Lutein is typically present in plant chromoplasts as long chain fatty esters, typically diesters, of acids such as palmitic and myristic acids, e.g. lutein dipalmitate, lutein dimyristate and lutein monomyristate. It has also been noted that once lutein is isolated from the plant, the lutein is biologically active in either the ester form or in the free form.

[0004] Additionally, the highly unsaturated unconjugated chain of carotenoids that makes up lutein is very sensitive to air, oxidizing agents, reducing agents, and structural alterations. Therefore, the loss of lutein during storage is well known. Further, lutein loss has been shown to begun as early as the raw material handling stage of the process. It has been documented that under carefully controlled conditions exposure to white fluorescent light resulted in the degradation of lutein in the range of 0.8-10.7% per day (please see Nahrung, 44, 38-41). However, ascorbic acid, an alkaline pH, low temperature (4°C) and darkness were found to retard the degradation of carotenoids, including lutein (please see Akad. Nauk. SSSR., 127, 1128-1131; Chem Abstr., 54, 11162). It has also been discovered that lutein and lutein esters are not stable compounds at room temperature or higher, and that free lutein is especially vulnerable to chemical and biological deterioration.

[0005] The preparation of stable and biologically active lutein and/or its esters from natural sources, such as Marigold petals, presents a challenging task. As seen in the following discussion, many patents have been issued on a method of obtaining such esters and the composition of the same.

[0006] United States Patent Number 5,382,714 (hereinafter the “714 patent”) discloses a method of isolating, purifying and recrystallizing substantially pure lutein, preferably from saponified marigold oleoresin in its pure free form, apart from chemical impurities and other carotenoids. It also discloses that as of the filing of the ‘714 patent, pure lutein suitable for human use had not been commercially available for use as a chemopreventative agent in clinical trials. It was also noted that pure lutein which is free of chemical contaminant is necessary to design and conduct proper human intervention studies.

[0007] The ‘714 patent noticed that esterified luteins are found with fatty acids in marigold petals, and that lutein could be produced upon saponification of the marigold lutein esters. However, the resulting lutein product was impure as it was contaminated with numerous chemical impurities.

[0008] The ‘714 patent disclosed a method of removing the lutein from the marigold petals without the chemical impurities. This method is disclosed as comprising the purification, preferably of a saponified marigold extract through the use of a series of filtrations and water/alcohol washes to obtain crude lutein crystals. These crystals are then dissolved in a halogenated organic solvent in which lutein is strongly soluble and then in a second organic solvent in which lutein is only partly soluble. This mixture is then cooled and the lutein is recrystallized in a high purity and it is then filtered and dried under vacuum.

[0009] United States Patent Number 5,648,564 (hereinafter the “564 patent”) discloses a process for forming, isolating and purifying xanthophyll crystals, preferably lutein, from marigold flower petals. It further disclosed that a xanthophyll diester-containing plant extract is saponified in a composition of propylene glycol and aqueous alkali to form xanthophyll crystals. It was also stated that the crystallization is achieved without the use of added organic solvents. The resulting crystals are then isolated and purified to produce substantially pure xanthophyll crystals suitable for human consumption.

[0010] The ‘564 patent also noted that the claimed method had several advantages over the prior art, including its ability to produce luteins suitable for

human consumption without using relatively toxic organic solvents during the isolation or crystallization steps. Additionally, the method does not require a recrystallization step.

[0011] United States Patent Number 4,048,203 (hereinafter the "203 patent") discloses a process for the purification of lutein-fatty acid esters from marigold flower petals or marigold petal oleoresins based on alkanol precipitation.

[0012] United States Patent Number 6,007,856 (hereinafter the "856 patent") discloses oil-in-water dispersions of β -carotene and other carotenoids that are stable against oxidation. The dispersions are prepared from water-dispersible beadlets comprising higher concentrations of colloidal β -carotene.

[0013] United States Patent Number 3,998,753 (hereinafter the "753 patent") discloses water dispersible carotenoid compositions in liquid or powder form which can be incorporated into pharmaceuticals, cosmetic preparations or animal foodstuffs. It also discloses the processes of preparing these dispersible carotenoid compositions.

[0014] United States Patent Number 4,929,774 (hereinafter the "774 patent") discloses a stable mixture of an oxidation-sensitive compound which also comprises triglycerides, complexing agents and coating substances.

[0015] United States Patent Number 5,536,504 (hereinafter the "504 patent") discloses methods for treating tumors with ultramicroemulsions from spontaneously dispersible concentrates containing xanthophyll esters, and new esters with xanthophyll compounds. Further, methods for the production of the concentrates are also disclosed.

Summary of the Invention

[0016] This invention relates to methods of producing lutein and lutein derivatives in a stable form as well as the individual compounds. Additionally, the invention is directed towards specific lutein derivatives which possess a long storage life.

Detailed Disclosure

[0017] Prior to the discoveries of this invention, those of ordinary skill used antioxidant vitamins and/or beadlets to stabilize lutein. These previously used methods primarily prevented the oxidation and the chemical and biological degradation of the lutein. One way in which the present invention is novel is that its stabilization of lutein and its esters goes beyond preventing oxidation. The present invention not only prevents oxidation of lutein and lutein esters, it also protects the

lutein compound from destabilizing factors such as oxidants, temperature, humidity, daylight, and UV rays (hereinafter "other factors") by obtaining lutein and lutein esters which protect against the other factors. It is also noted that these factors effect the stability of lutein and lutein esters during the extraction process, as well as the industrial processing of the same for use in final products. Finally, it was noted that vitamin-based antioxidants can prevent the deterioration of lutein, but it was not known whether they would be effective against the other factors.

[0018] The present invention provides a method of protecting lutein against direct and indirect physical, chemical, and biological factors which contribute to the deterioration of lutein and lutein esters. This method protects lutein and lutein esters from both xenobiotic compounds and the environmental elements. The totality of the protective action of the method is referred to hereinafter as XENOGARD (see Table I). The method of the present invention is two-fold. It is based on a unique process of isolation, which provides lutein and lutein esters chemically and less physically stressed in their isolated forms. The resulting product of the XENOGARD method is also more resistant to chemical/biological deterioration. Additionally, the invention provides a method of combining lutein and lutein esters with at least one stabilizing compound, such as, but not limited to, 0.01-10 wt % tetrahydrocurcuminoids, 0.01-10 wt % of curcuminoids, or 0.01-10 wt% carnosic acid.

[0019] It should be noted that tetrahydrocurcuminoids and curcuminoids are phenolic in nature, and that they are also recognized as antioxidants which provide protection against free radicals and also prevent the generation of free radicals. Additionally, curcuminoids are known to absorb UV rays and to protect pharmaceutical preparations from physio-chemical deterioration. Curcuminoids have also been found to prevent pyrolysis which is the high temperature related deterioration of processed food and nutrients. Curcuminoids are also recognized for their anti-microbial properties in preventing the growth of bacteria or fungi, which is a factor that is detrimental to the stability of lutein and lutein esters especially in humid conditions. Tetracurcuminoids, which are derivatives of curcuminoids, are particularly effective in scavenging free radicals and are also complementary to the action of curcuminoids which are primarily effective in preventing free radicals from occurring in biological systems. Carnosic acid is compatible and complementary with both curcuminoids and tetracurcuminoids. It is an antioxidant and anti-microbial

compound similar to curcuminoids and tetracurcuminoids' broad action consisting of free radical prevention and scavenging action.

[0020] The process of obtaining XENOGARD lutein and lutein esters proceeds as follows. First, marigold flower petals are harvested. These petals are then shade dried, crushed and left at room temperature for a period of time, preferably 3 to 4 hours. The resulting material is then treated with a solvent, preferably an alcohol, and more preferably ethyl alcohol, and incubated, preferably for 5 hours at room temperature. A preferable ratio of solvent to marigold flower petals is 100 kg of the marigold material to 400 L of ethyl alcohol. Following the incubation period, the resulting solution is collected. This procedure is then repeated, preferably at least two additional times, and the combined alcohol extracts are combined. If the process is repeated two times and the preferred ratio is used then the total solution should amount to about 1250 L. The extracts are then diluted with water to obtain an alcohol solution, which is preferably 70% by weight alcohol.

[0021] Alternatively, the shade dried petals can be treated with supercritical carbon dioxide for a period of time, preferably 10 hours, and after the evaporation of the carbon dioxide occurs, the remaining oleoresin is diluted with an alcohol, preferably ethanol, and water, as described above, to obtain a diluted alcohol solution, preferably a 70% alcohol solution.

[0022] This extract of marigold petals in the alcohol solution may then be used to obtain lutein esters or free lutein by subjecting the extract to hydrolysis. This process entails passing the oleoresin in the alcohol solution through a column packed with an anion exchange resin. Preferably, this is performed at a rate of 20-50 L per hour. Suitable resins include Amberjet 4200(cl), Amberlite IRA 410, Amberlite IRA 900, Dowex 1x2-100, Dowex 22cl, Dowex Marathon A2, Dowex MSA 1, Dowex 550 A, all of which are Rohm-Haas or Dow products.

[0023] Upon completion of the hydrolysis, the eluents are collected and diluted with deionized water with a strong and vigorous agitation. The resulting lutein crystals are filtered, collected, and dried in vacuum with the exclusion of oxygen.

[0024] These lutein crystals or lutein esters can be combined subsequent to their isolation with a stabilizing mixture of tetrahydrocurcuminoids in an amount of 0.01-10.0 wt %, curcuminoids in an amount of 0.01-10.0 wt %, and carsonic acid in an amount of 0.01-10.0 wt % to form the XENOGARD composition. Preferably each of the stabilizing ingredients are present in an amount of 0.1 wt. %. The XENOGARD

composition of lutein or esters of lutein are then packaged under nitrogen atmosphere, sealed, and stored until further use. An additional XENOGARD compositions of lutein and lutein esters can be prepared in the form of a soft extract comprising at least 50 wt % marigold oleoresin, 45 wt % vegetable oil (preferably refined Soya oil), 1.5 wt % citric acid, and 2 wt % natural tocopherol.

[0025] The XENOGARD lutein and lutein esters can be further stabilized by a coating process. An example of such a coating process would involve combining a sugar, preferably sucrose, preferably in as slurry form, with water (preferably distilled water) and the XENOGARD composition to obtain a uniform blend. Preferably, the ratio used in forming the uniform blend would entail 450 g of sucrose to 100 ml of distilled water to 250 mg of the XENOGARD composition. Starch is then added to the uniform blend and the resulting mixture is then charged to a mixer which is run until the mixture is blended, preferably 30 minutes. Also, the preferred ratio used in determining the appropriate amount of starch to add is 630 g of starch to 800 g of the uniform blend. PVP (preferably in a ratio 450 g to 1430 g of starch solution) combined in a solvent (preferably 70% ethanol solution) is then added to the starch solution and blended to form a dough with a preferred moisture content of less than 5%, adjusted at 30°C under vacuum. The dough is then fed into a granulator preferably fitted with a 30 mesh screen and the granules are collected in trays which have been preferably lubricated with talc and dried under a vacuum for 8-12 hours. The dried granules are then transferred to a coating pan (suitably approximately 350 g of PVP and 40 g of paprika resin). The resulting granules are dried again under vacuum at 30°C for about 6-8 hours, and sifted and packed.

[0026] An example of a XENOGARD product is Zealutein®. Zealutein® is comprised of lutein, zexanthin, piperine (Bioperine®), other carotenoids, and other stabilizing components. Figure 1 proves Zealutein®'s antioxidant activities, whereas Figures 2 and 3 illustrate its stability in two different forms. Further, it has been shown that the Zealutein® Regular Granules are stable for three years under normal conditions, whereas Zealutein® BJ-80 Mesh is stable for two years under normal conditions. The composition of both of these forms of Zealutein® are disclosed in Figures 4 and 5. However, the final composition of Zealutein® comprises lutein in an amount not less than 5 weight percent of the final product, Zeaxanthin in an amount not less than 1 weight percent of the final product, Piperine (and preferably

Bioperin®) in an amount not less than 2 weight percent of the final product, and other carotenoids in an amount not less than 1 weight percent of the final product.

[0027] Additionally, further stabilizing components which may be used in the present invention include other carotenoids in the form of Capsanthin ester, Capsorubin ester, Zeaxanthin ester, Cryptoxanthin ester, and beta-carotene ester. These stabilizing components may be 1-10 weight percent of the final product. Additionally, paprika carotenoids are a potential source of stabilizing components, provided the paprika carotenoids are in the form of esters. Additions to the stabilizing components may also be added. These added compounds include tetracurcuminoids, Rosmarinic acid, green tea catechins and other similar natural antioxidants.

DRAWINGS

Figure 1: Figure 1 illustrates the Rancimat testing of Zealutein® and shows that Zealutein® possesses antioxidant properties.

Figure 2: Figure 2 illustrates a comparison of Zealutein® Regular Granules against lutein in which the stability of each has been tested at 30 day intervals in conditions of 40°C and 75% relative humidity.

Figure 3: Figure 3 illustrates a comparison of Zealutein® BJ-80 Mesh against lutein in which the stability of each has been tested at 30 day intervals in conditions of 40°C and 75% relative humidity.

Figure 4: Figure 4 lists the requirements and composition for Zealutein® BJ-80 Mesh.

Figure 5: Figure 5 lists the requirements and composition for Zealutein® Regular Granules.

Figure 6: Figure 6 illustrates the results of testing the effect of a topical application of zealutein on 12 O-tetradecanoylphorbol-13-acetate (TPA)-induced edema of mouse ears.

Figure 7: Figure 7 illustrates the dramatic difference in the percent of mice with cancer when being treated with a topical application of TPA when one group is treated with TPA alone and another is treated with TPA and zealutein.

Figure 8: Figure 8 illustrates the results of testing the inhibitory effect of zealutein on 12 O-tetradecanoylphorbol-13-acetate (TPA)-induced skin tumor promotion in CD-1 mice previously initiated with 7,12-dimethylbenz[a]anthracene (DBMA).

References Cited

Sies, H., Stahl, W., Sundquist, A.R. (1992) Antioxidant functions of vitamins. Vitamins E and C, beta-carotene, and other carotenoids. Ann. N.Y. Acad. Sci., 669, 7-20.

Chew, B.P., Wong, M.W., and Wong, T.S. (1996) Effects of lutein from marigold extract on immunity and growth of mammary tumors in mice. Anticancer Res., 16, 3689-3694.

Jyonouchi, H., Zhang, L., Gross, M. and Tomita, Y. (1994) Immunomodulating actions of carotenoids: Enhancement of in vivo and in vitro antibody production to T-dependent antigens. Nutr. Cancer, 21(1), 47-58.

Shi, X.M. and Chen, F. (1997) Stability of lutein under various storage conditions Nahrung, 44, 38-41.

Sapozhnikov, D.I., Eidelman, Z.M., Bazhanova, N.V., and Popova, O.F. (1959) Blocking of the light reaction by hydroxylamine in the transformation of xanthophylls. Doklady. Akad. Nauk. SSSR., 127, 1128-1131; Chem Abstr., 54, 11162.

United States Patent Number 5,382,714

United States Patent Number 5,648,564

United States Patent Number 4,048,203

United States Patent Number 6,007,856

United States Patent Number 3,998,753

United States Patent Number 4,929,774

United States Patent Number 5,536,504

CLAIMS

1. A process for producing a stabilized lutein composition comprising:
 - a) shade drying marigold flower petals;
 - b) extracting the dried marigold flower petals of step a) with a solvent to produce an extract solution;
 - c) passing the extract solution through a column packed with an anion exchange resin to obtain an eluent;
 - d) diluting the eluent to form a diluted solution;
 - e) and recovering lutein crystals from the diluted solution.
2. The process of claim 1, wherein the shade drying of the marigold petals is performed at room temperature for 3 to 4 hours.
3. The process of claim 2, wherein step b) is performed in the proportion of 400 L of ethyl alcohol to 100 kg of dried marigold petals and wherein step b) further comprises incubating the mixture of dried flower petals and ethyl alcohol for 5 hours at room temperature.
4. The process of claim 3, wherein the solvent of step b) is an alcohol.
5. The process of claim 4, wherein the alcohol of step b) is ethyl alcohol.
6. The process of claim 3, wherein step b) further comprises draining the mixture of ethyl alcohol and dried marigold petals and collecting the liquid in an appropriate container, repeating the procedure at least one additional time with the same marigold petals, and diluting the collected liquid with sufficient amounts of water to obtain a 70% alcohol solution.
7. The process of claim 1, wherein the eluent of step d) is diluted with deionized water.
8. The process of claim 1, further comprising the drying of the recovered lutein crystals in a vacuum and the packing of the dried lutein crystals in a nitrogen atmosphere.
9. The process of claim 8, further comprising the stabilization of the composition of formula (I) or a derivative thereof, wherein said process further comprises prior to the packing step, combining the lutein crystals with at least one of tetrahydrocurcuminoids in the amount of 0.001-0.1 wt %, curcuminoids in the amount of 0.001-0.1 wt % and camosic acid in the amount of 0.001-0.1 wt % to form a XENOGARD composition.

10. The process of claim 9, further comprising the further stabilization of the composition of formula (I) or a derivative thereof, wherein said process further comprises prior to the packing step:

- i) combining a sucrose slurry with the XENOGARD composition in the ratio of one part of XENOGARD to 1-10 parts of sucrose to form a uniform blend;
- ii) adding 10 parts of starch to the uniform blend of step i) to form a starch mixture;
- iii) adding an ethanol solution of PVP in an amount of 1 part of PVP to 0.1-10 parts of the XENOGARD composition, and drying the resulting mixture to the starch mixture of step ii) to form an ethanol starch mixture.

11. The process of claim 10, further comprising:

- iv) forming the ethanol starch mixture granules and collecting the granules in trays lubricated with talc and drying the granules in a vacuum; and
- v) transferring the dried granules to a coating pan, drying the dried granules in a vacuum, sifting said dried granules and packing the dried granules.

12. The process of claim 11, wherein the coating pan of step v) is coated with PVP and paprika resin in a proportion of approximately 9 parts of PVP to 1 part of paprika resin.

13. A process for producing a stabilized lutein composition comprising:

- a) shade drying marigold flower petals;
- b) treating the dried marigold flower petals of step a) with supercritical carbon dioxide;
- c) allowing the supercritical carbon dioxide to evaporate to leave an oleoresin;
- d) passing an alcohol solution of the oleoresin through a column packed with an anion exchange resin; and
- e) collecting lutein crystals from the eluent.

14. The process of claim 13, wherein the marigold flower petals are dried at room temperature for 3 to 4 hours

15. The process of claim 14, wherein dried marigold flower petals are treated with supercritical carbon dioxide for 10 hours.

16. The process of claim 13, wherein the alcohol solution is a 70% alcohol solution.

17. The process of claim 13, further comprising packaging the collected lutein crystals under a nitrogen atmosphere.
18. The process of claim 13, further comprising the stabilization of the composition of formula (I) or a derivative thereof, wherein said process further comprises prior to the packing step, combining the lutein crystals with at least one of tetrahydrocurcuminoids in the amount of 0.001-0.1 wt %, curcuminoids in the amount of 0.001-0.1 wt % and carnosic acid in the amount of 0.001-0.1 wt % to form a XENOGARD composition.
19. The process of claim 18, further comprising the further stabilization of the composition of formula (I) or a derivative thereof, wherein said process further comprises prior to the packing step:
- i) combining a sucrose slurry with the XENOGARD composition in the ratio of one part of XENOGARD to 1-10 parts of sucrose to form a uniform blend;
 - ii) adding 10 parts of starch to the uniform blend of step i) to form a starch mixture;
 - iii) adding an ethanol solution of PVP in an amount of 1 part of PVP to 0.1-10 parts of the XENOGARD composition, and drying the resulting mixture to the starch mixture of step ii) to form an ethanol starch mixture.
20. The process of claim 19, further comprising:
- iv) forming the ethanol starch mixture granules and collecting the granules in trays lubricated with talc and drying the granules in a vacuum; and
 - v) transferring the dried granules to a coating pan, drying the dried granules in a vacuum, sifting said dried granules and packing the dried granules.
21. The process of claim 20, wherein the coating pan of step v) is coated with PVP and paprika resin in a proportion of approximately 9 parts of PVP to 1 part of paprika resin.
21. A composition comprising at least one of lutein and lutein esters and 0.001-0.3 parts of stabilizer compounds, tetrahydrocurcuminoids, curcuminoids, and carnosic acid, and mixtures of two or more of such stabilizers.
23. The composition of claim 22, wherein said composition comprises lutein or lutein esters an antioxidant effective amount, and tetrahydrocurcuminoids, curcuminoids, and carnosic acid each in a proportion of 0.01-10.0 wt %.

24. The composition of claim 22, wherein said composition comprises lutein or lutein esters in a biologically effective amount and tetrahydrocurcuminoids, in a proportion of 0.01-10.0 wt %.
25. The composition of claim 22, wherein said composition comprises lutein or lutein esters in a biologically effective amount and curcuminoids in a proportion of 0.01-10.0 wt %.
26. The composition of claim 22, wherein said composition comprises lutein or lutein esters in a biologically effective amount and carnosic acid a proportion of 0.01-10.0 wt %.
27. The composition of claim 22, wherein said composition comprises lutein or lutein esters in a biologically effective amount and tetrahydrocurcuminoids, curcuminoids, and carnosic acid each in a proportion of 0.01- 10.0 wt %.
28. The composition of claim 22, wherein said composition comprises lutein or lutein esters, tetrahydrocurcuminoids, curcuminoids, and carnosic acid each in equal amounts.
29. A XENOGARD composition, wherein said composition comprises a soft extract composed of marigold oleoresin obtained from exposing shade dried crushed marigold petals to supercritical carbon dioxide, vegetable oil, citric acid, and natural tocopherol, each in an amount of 0.5-5.0% by weight.
30. The XENOGARD composition of claim 29, wherein said vegetable oil is refined Soya oil.
31. A XENOGARD composition, wherein said composition comprises lutein in an amount of not less than 5.0 % by weight, Zeaxanthin in an amount of not less than 1.0 % by weight, piperine in an amount of not less than 1.0 % by weight, and other carotenoids in an amount of not less than 1.0 % by weight.
32. The XENOGARD composition of claim 31, wherein said composition further comprises one or more stabilizing components selected from the group consisting of zeaxanthin ester, cryptoxanthin ester, beta-carotene ester in an amount of not less than 1.0 % by weight, but no more than 10.0 % by weight.
33. The XENOGARD composition of claim 20, wherein said composition further comprises one or more stabilizing components selected from the group consisting of paprika carotenoid esters, tetrahydrocurcuminoids, rosmarinic acid, green tea catechins in an amount of not less than 1.0 % by weight, but no more than 10.0 % by weight.

34. The XENOGARD composition of claim 31, wherein said composition comprises zeaxanthin in an amount of not less than 1.0 % by weight, lutein in an amount of not less than 5.0 % by weight, piperine in an amount of not less than 1.0% by weight, and at least one ester of capsanthin, capsorubin, zeaxanthin, beta-carotene, or cryptoxanthin in an amount of not less than 1.0 % by weight.
35. The XENOGARD composition of claim 34, wherein piperine is present in an amount of not less than 2.0 % by weight.
36. A XENOGARD composition, wherein said composition comprises lutein in an amount of not less than 5.0 % by weight, Zeaxanthin in an amount of not less than 1.0 % by weight, piperine in an amount of no more than 1.0 % by weight, and other carotenoids in an amount of not less than 1.0 % by weight.

FIGURE 1

Index	Induction Time (Hr.)	Antioxidant
Control (lard only)	2.32	
Zealutein	3.10	1.34

Zealutein has some antioxidant activity against lipid peroxidation.

FIGURE 2

ZEALUTEIN (XENOGARD) REGULAR (GRANULES)**Stability Data of batch No. C11315**

Period of keeping	Storage condition: RT(30-33° C)		Storage Condition: 40° C/RH 75%		<u>Remarks</u>
	<u>Assay in %</u>		<u>Assay in %</u>		
	Lutein	Zeaxanthin	Lutein	Zeaxanthin	90 days stable
Initial	8.20	1.19	8.2	1.19	
30 days	8.13	1.20	7.99	1.16	
60 days	8.12	1.16	7.96	1.11	
90 days	6.48	1.12	5.04	1.08	

This is stable for three years under normal condition

FIGURE 3

ZEALUTEIN BJ – 80 MESH**STABILITY STUDIES****Stability Data of batch No. C11293**

Period of keeping	Storage condition: RT(30-33° C)		Storage Condition: 40° C/RH 75%		<u>Remarks</u>
	<u>Assay in %</u>		<u>Assay in %</u>		
	Lutein	Zeaxanthin	Lutein	Zeaxanthin	60 days stable
Initial	8.5	1.27	8.5	1.27	
30 days	7.80	1.22	7.74	1.20	
60 days	7.24	1.19	6.82	1.12	
90 days	4.82	1.15	3.93	1.12	

This is stable for two years under normal condition

FIGURE 4

FINISHED PRODUCT SPECIFICATION

STANDARDS AND LIMITS

**ZEALUTEIN™ - BJ (80 MESH)
(1% ZEAXANTHIN, 5% LUTEIN, 2% PIPERINE)**

Description	Orange to orange red powder with characteristic odour.
Identification	To comply by HPLC
Loss on drying	Not more than 5.0%
Solubility	Partly soluble in acetone and in chloroform, sparingly soluble in alcohol, insoluble in water.
Ash content	Not more than 10.0%
Heavy metals	Not more than 20ppm
Arsenic	Not more than 1ppm
Lead	Not more than 10ppm
Tapped Bulk Density	Between 0.40g/ml and 1.0g/ml
Loose Bulk Density	Between 0.35g/ml and 0.70g/ml
Sieve Test (passes through)	
-80 mesh	Not less than 95.0%
Assay by HPLC	
-Content of Zeaxanthin	Not less than 1.0%
-Content of Lutein	Not less than 5.0%
-Content of Piperine	Not less than 2.0%
-Content of other Carotenoids	
Content of other Carotenoids by UV (Esters of Capsanthin, Capsorubin, Zeaxanthin, β -Carotene and Cryptoxanthin)	Not less than 1.0%

FIGURE 5

FINISHED PRODUCT SPECIFICATION**STANDARDS AND LIMITS****ZEALUTEIN™ -REGULAR
(1% ZEAXANTHIN, 5% LUTEIN, 2% PIPERINE)**

Description	Brick red granular powder with characteristic odour.
Identification	To comply by HPLC
Loss on drying	Not more than 5.0%
Solubility	Partly soluble in acetone and in chloroform, sparingly soluble in alcohol, insoluble in water.
Ash content	Not more than 10.0%
Heavy metals	Not more than 20ppm
Arsenic	Not more than 1ppm
Lead	Not more than 10ppm
Tapped Bulk Density	Between 0.40g/ml and 1.0g/ml
Loose Bulk Density	Between 0.35g/ml and 0.70g/ml
Sieve Test (passes through)	
-20 mesh	Not less than 100.0%
-40 mesh	Not less than 60.0%
-80 mesh	Not less than 30.0%
Assay by HPLC	
-Content of Zeaxanthin	Not less than 1.0%
-Content of Lutein	Not less than 5.0%
-Content of Piperine	Not less than 2.0%
Content of other Carotenoids by UV (Esters of Capsanthin, Capsorubin, Zeaxanthin, β -Carotene and Cryptoxanthin)	Not less than 1.0%

FIGURE 6

Table 1

Effect of topical application of zealutein on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced edema of mouse ears

Treatment	Number of mice per group	Weight Per ear punch (mg)	Percent inhibition
<u>Experiment 1</u>			
1. Acetone	4	6.46±0.15	-
2. TPA (1 nmol)	5	15.30±0.87	-
3. TPA (1 nmol) + zealutein (0.04 mg)	4	10.93±0.77	49.9
4. TPA (1 nmol) + zealutein (0.12 mg)	4	8.89±0.69	72.7
5. TPA (1 nmol) + zealution (0.36 mg)	4	7.88±0.23	84.0
<u>Experiment 2</u>			
1. Acetone	6	6.69±0.20	-
2. TPA (1 nmol)	11	13.70±0.61	-
3. TPA (1 nmol) + zealutein (0.04 mg)	6	10.53±0.42	45.2
4. TPA (1 nmol) + zealutein (0.12 mg)	6	8.57±0.35	73.2
6. TPA (1 nmol) + zealutein (0.36 mg)	6	7.71±0.31	85.5
7. TPA (1 nmol) + curcumin (0.04 mg)	6	10.50±0.70	45.6
8. TPA (1 nmol) + curcumin (0.12 mg)	6	7.40±0.31	89.9
<u>Experiment 3</u>			
1. Acetone	5	6.61±0.25	-
2. TPA (1 nmol)	5	14.61±0.77	-
3. TPA (1 nmol) + lutein (0.072 mg)	5	10.04±0.57	57.1
4. TPA (1 nmol) + lutein (0.36 mg)	5	8.81±0.37	72.5

Female CD-1 mice (25-28 days old) were treated topically on both ears with 20 µl acetone, TPA (1 nmol), or TPA (1 nmol) together with test compound in 20 µl acetone. Five hours later, the mice were killed by cervical dislocation and ear punches were weighed. Data are expressed as the mean±SE.

FIGURE 7




FIGURE 8

Inhibitory effect of zealutein on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin tumor promotion in CD-1 mice previously initiated with 7,12-dimethylbenz[a]anthracene (DMBA)

Group	Treatment	Number of mice per group	Body weight per mouse (g)	Percent of mice with tumors	Tumors per mouse	Tumor volume tumor (mm ³)	Tumor volume per mouse (all mice) (mm ³)	Number of tumors diameter (> 5 mm)
1	DMBA + Acetone	30	31.7±0.6	100.0%	0	0	0	0
2	DMBA + TPA (5nmol)	16	32.5±0.7	100.0%	21.8±2.0	7.7±1.2	176.8±25.1	20
6	DMBA + Zealutein 5µg	16	32.2±0.6	87.5% (-12.5%)	5.8±1.4 (-73.4%)	6.6±3.8 (-14.3%)	22.7±7.7 (-87.2%)	0 (-100%)

Female CD-1 mice (7-8 weeks old; 30 mice per group) were initiated with a single dose of 7,12-dimethylbenz[a]anthracene (DMBA). One week later, the mice were promoted with 200 µl acetone, TPA (5 nmol) in 20 µl acetone or TPA (5 nmol) + zealutein (3 mg) in 200 µl acetone for 16 weeks. Data are expressed as mean ± SE.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/02423

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C403/02 C07C403/14 C07C35/21 B01D11/02 A23L1/28
A61P17/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C B01D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, COMPENDEX, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 382 714 A (KHACHIK FREDERICK) 17 January 1995 (1995-01-17) cited in the application column 2, line 18 - line 50 column 2, line 65 - column 3, line 8 column 3, line 30 - line 47	1-21
X	column 3, line 59 - column 4, line 8 column 4, line 27 - line 42 column 4, line 53 - line 55 column 5, line 17 - line 23 claims 1-20; example 3 ---	22
A	WO 99 20587 A (KHACHIK FREDERICK ;TECHNOLOGY LIAISON OFF OF (US)) 29 April 1999 (1999-04-29)	1-21
X	page 4 -page 5 page 7 -page 8 page 10; claims 5-13 --- -/-	22



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

20 June 2002

Date of mailing of the international search report

05/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Seelmann, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/02423

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	A. SABAGIO ET AL.: "Preparation of lutein from marigold flowers and esterification to their myristates" ANALYTICAL SCIENCES, vol. 13, 1997, pages 1025-1028, XP002202970	1-21
X	experimental, page 1025	22
A	US 5 017 397 A (NGUYEN UY ET AL) 21 May 1991 (1991-05-21) column 2, line 21 - line 32 column 3, line 2 - line 9 column 4, line 34 - line 45 column 5, line 26 - line 32	1-21
A	F. TATEO ET AL.: "Rosmarinus officinalis L. Extract production antioxidant and Antimutagenic Activity" PERFUMER & FLAVORIST, vol. 13, 1988, pages 48-54, XP001079906 page 48, right-hand column page 49, right-hand column; figure 2B page 51 page 53	1-21
X	SABINSA CORPORATION: "tetrahydrocurcuminoids" INTERNET, 'Online! 2000, XP002202971 Retrieved from the Internet: <URL:http://www.tetrahydrocurcuminoids.com > 'retrieved on 2002-06-03! the whole document	22-36
X	SABINSA CORPORATION: "ZeaLutein" INTERNET, 'Online! 2000, XP002202972 Retrieved from the Internet: <URL:http://www.zealutein.com> 'retrieved on 2002-06-03! the whole document	22-36
X	US 5 972 993 A (AVON PRODUCTS INC) 26 October 1999 (1999-10-26) column 4, line 41 - line 65 column 5, line 63 -column 6, line 1 column 6, line 49 - line 57 column 9, line 41 - line 41 claims 1,6,12; example 2	22,23,26

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/02423

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	X.-M. SHI ET AL.: "Stability of lutein under various storage conditions" NAHRUNG, vol. 41, no. 1, 1997, pages 38-41, XP001079540 cited in the application page 38 results and discussion, pages 39-40 ---	22-30
Y	T. OSAWA ET AL.: "Antioxidative activity of tetrahydrocurcuminoids" BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, vol. 59, no. 9, 1995, pages 1609-1612, XP001024945 page 1609 page 1611, left-hand column ---	22-30
A	US 5 972 382 A (SABINSA CORPORATION) 26 October 1999 (1999-10-26) column 2, line 48 - line 53 column 4, line 57 -column 5, line 3 claims 7,8; examples 4,7,14 -----	31-36

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/02423

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5382714	A	17-01-1995	AT 191475 T	15-04-2000
			DE 69516031 D1	11-05-2000
			DE 69516031 T2	14-09-2000
			DK 672655 T3	03-07-2000
			EP 0672655 A1	20-09-1995
			ES 2147261 T3	01-09-2000
			JP 2790212 B2	27-08-1998
			JP 8092205 A	09-04-1996
			KR 214430 B1	02-08-1999
			PT 672655 T	29-09-2000
WO 9920587	A	29-04-1999	AU 1271999 A	10-05-1999
			WO 9920587 A1	29-04-1999
US 5017397	A	21-05-1991	AT 112141 T	15-10-1994
			CA 2040816 A1	26-10-1991
			DE 69104257 D1	03-11-1994
			DE 69104257 T2	24-05-1995
			DK 454097 T3	03-04-1995
			EP 0454097 A1	30-10-1991
			ES 2064798 T3	01-02-1995
			JP 3194984 B2	06-08-2001
			JP 4227680 A	17-08-1992
US 5972993	A	26-10-1999	NONE	
US 5972382	A	26-10-1999	US 5744161 A	28-04-1998
			US 5536506 A	16-07-1996
			AT 204757 T	15-09-2001
			AU 4128796 A	11-09-1996
			CA 2247467 A1	29-08-1996
			DE 69522477 D1	04-10-2001
			DE 69522477 T2	29-05-2002
			DK 810868 T3	26-11-2001
			EP 0810868 A1	10-12-1997
			ES 2161914 T3	16-12-2001
			JP 11500725 T	19-01-1999
			PT 810868 T	28-02-2002
			WO 9625939 A1	29-08-1996

